Render Target: STATIC
Render Timestamp: 2024-12-26T11:16:21.649Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-09-30 01:59:13.161
Product last modified at: 2024-12-04T21:15:07.687Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

BCL2L13 (E6G1Q) Rabbit mAb #61974

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa) 90
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:100

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    BCL2L13 (E6G1Q) Rabbit mAb recognizes endogenous levels of total BCL2L13 protein.

    Species Reactivity:

    Human, Mouse, Rat

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu267 of human BCL2L13 protein.

    Background

    BCL2L13 (Bcl-2-like protein 13, Bcl-rambo) is an atypical member of the Bcl-2 family of proteins that regulate apoptosis at the mitochondria (1). While it contains conserved Bcl-2 homology (BH) domains -1, -2, -3, and -4, it has a unique C-terminal region and does not interact with other Bcl-2 family members (1). BCL2L13 may regulate apoptosis in a cellular context manner (reviewed in 2). It was originally identified as a pro-apoptotic protein with activity dependent on its C-terminal region (1). Interaction with the adenine nucleotide translocator (ANT) suppresses the ADP/ATP-dependent translocation activity of ANT (3). Other studies have found that BCL2L13 can inhibit apoptosis in glioblastoma and tumor growth (4). These studies found that BCL2L13 binds to pro-apoptotic ceramide synthases 2 (CerS2) and 6 (CerS6) and blocks homo- and heteromeric CerS2/6 complex formation and activity. Studies have also found that BCL2L13 can regulate mitochondrial fragmentation and can bind to LC3 to facilitate the clearance of damaged mitochondria through mitophagy (5,6).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.